Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Dysglycemia Cause in Overweight Adults, Teens

Diabetes Care; ePub 2017 Nov 28; Chen, et al

Adults and adolescents have dissimilar underlying defects that lead to dysglycemia, according to a study involving 139 individuals. Participants included adults (n=89) and adolescents (n=50) with normal glucose tolerance (NGT), dysglycemia, or type 2 diabetes. Investigators used oral glucose tolerance test results for C-peptide and insulin/glucose minimal modeling, and compared insulin secretion and insulin sensitivity across glycemic stages and between age groups at each stage. Among the results:

  • Adolescents with dysglycemia had marked insulin resistance, with median insulin sensitivity index score of 1.8, vs 5.0 for adults.
  • The nature of β-cell dysfunction across stages of dysglycemia differed between the groups.
  • There were higher levels of insulin secretion in adolescents compared with adults.
  • Adults showed stepwise impairments in static insulin secretion.
  • Adolescents showed diabetes-related impairment in dynamic secretion.

The authors noted that their findings point to the need for different diabetes prevention approaches in youths and adults.

Citation:

Chen M, Chandramouli A, Considine R, Hannon T, Mather K. Comparison of β-Cell function between overweight/obese adults and adolescents across the spectrum of glycemia. [Published online ahead of print November 28, 2017]. Diabetes Care. doi:10.2337/dc17-1373.

This Week's Must Reads

Abdominal Obesity and Diabetes Link Evaluated, Diabetes Obes Metab; ePub 2017 Dec 1; Caspard, et al

The Limits of Intensive Glucose Lowering in T2D, Diabetes Care; ePub 2017 Dec 5; Koska, Saremi, et al

How Does Empagliflozin Reduce CV Mortality?, Diabetes Care; ePub 2017 Dec 4; Inzucchi, et al

FDA Approves Admelog ‘Follow-On’ Insulin, FDA news release; 2017 Dec 11

Must Reads in Diabetes

Abdominal Obesity and Diabetes Link Evaluated, Diabetes Obes Metab; ePub 2017 Dec 1; Caspard, et al

The Limits of Intensive Glucose Lowering in T2D, Diabetes Care; ePub 2017 Dec 5; Koska, Saremi, et al

How Does Empagliflozin Reduce CV Mortality?, Diabetes Care; ePub 2017 Dec 4; Inzucchi, et al

FDA Approves Admelog ‘Follow-On’ Insulin, FDA news release; 2017 Dec 11